Schmalfeldt B et al. reported dramatic increases in MMP2, MMP9, and active MMP2 in advanced ovarian cancers and omentum metastases compared with benign ovarian tumors and tumors with low malignant potential14. This evidence concerns the gene MMP2 and ovarian benign neoplasm.